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John J. Moulds, MT(ASCP)SBB
John J. Moulds had a prolific career in immunohematology. 
His name is synonymous with analytic scientist. From my 
perspective, John’s most admirable trait and one that we 
should all strive for was his genuine and incisive interest in 
the case, whether presented by an esteemed colleague or a 
student. He endeavored to find the reason for the results and 
what it meant for the patient’s care. He was a truth seeker, 
eagerly remembering the past to help solve today’s case! One 
of my favorite recollections is talking at length (was there any 
other way with John?) about a very minute detail of a most 
complex case from the past, which of course was always the 
clue that led to the resolution. He was always the one with the 
corporate memory; it was John who could tell us the family 
members by name and type, which laboratory studied the 
case, the exact reactivity of the samples in each of the media, 
and the conclusion for the case.
Immunohematology benefitted immeasurably from his 
experience and ideas, and we miss his presence. John served on 
the editorial board of Immunohematology for many years, and 
I and the rest of the editorial board members are truly grateful 
for his contributions and opinions. In one of his last attendances 
at the annual editorial board meetings, John offered to do the 
centerfold. Let me explain. Immunohematology has a new 
feature that will be used, when appropriate, to help educate our 
staff and students. This is a page within the journal containing 
serologic, technical, or blood group information that can 
be separated and posted for educational purposes, in other 
words, a centerfold. Alas, John did not get to complete this. 
But the first centerfold, with his beloved “orphan” antigens of 
the 700 series, appears in this issue. The tributes in this issue 
give credence to the intensity of his aura in the transfusion 
medicine science community. 
Sandra Nance, MS, MT(ASCP)SBB
Editor-in-Chief, Immunohematology
American Red Cross Biomedical Services
Penn-Jersey Region
Philadelphia, Pennsylvania
For the 2011 South Central Association of Blood Banks (SCABB) 
annual meeting, I nominated John Moulds for the Larry L. Trow 
Memorial Education Award. This award is for people who have 
shown excellence in education in blood banking. The following is 
a reiteration of my nomination of John for the award, which, by 
the way, he won.
John Moulds spent his career providing education to 
the blood bank community in many different aspects. I first 
met John while I was an SBB student when he was working 
at Gamma Biologicals in Houston, Texas. I do believe my 
knowledge of the Lewis system and my philosophy of antibody 
identification came from that short week with John. I will 
never forget him saying, “Don’t look for unicorns until you 
have ruled out the zebras.”
Besides his work with Gamma, he worked for Ortho as 
a Senior Research Fellow and more recently as the Director 
of Scientific Support Services at LifeShare Blood Center. No 
matter what his job was, he always found time to teach at local, 
national, and international meetings. In 1972, he founded and 
was director of the Serum, Cells, and Rare Fluid (SCARF) 
International Exchange. John has chaired committees for 
AABB and SCABB; he was a peer reviewer for Vox Sanguinis 
and Transfusion, and served on the editorial board for 
Immunohematology.
John’s association with my SBB program prompted me 
to nominate him for the Larry L. Trow Memorial Education 
Award for Education. He spent one day with my SBB students 
telling them how to become the best blood bankers ever, and 
he did this on his own time and with his own money! When 
answering students’ questions, he would ask beforehand, “Do 
you want the long or the short version?” I do think his goal 
was to instill his love of antibodies in the future blood bankers. 
He had my students on the edge of their seats waiting for the 
next story, the next tidbit of information. He was a role model 
for teachers and for anyone who wanted to make antibody 
identification their life’s work. He would pick up the phone 
and talk to somebody who was emailing about a problem. The 
email may have been a broad email that just happened to get to 
him, but he would take the time to actually pick up the phone 
and call. John taught each time he answered a question. He 
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had a rare gift of being able to teach with a flair that left the 
students in awe as they knew they were hearing words from 
the master!
John has won the Ivor Dunsford Memorial Award from 
AABB, the L. Jean Stubbins Award from SCABB, the A. 
Konugres Lectureship from MABB, and the Sally Frank 
Memorial Award from NBF/AABB, and was recently honored 
at the 49th SCABB meeting with the Scientific Award Lecturer. 
But to me the most important award is missing, and that is the 
Larry Trow Memorial Award for Education. John was a true 
educator and should be the winner of every education award 
possible. Education has been his true calling.
Janet Vincent, MS, SBB(ASCP)
Education Coordinator, SBB Program
University of Texas Medical Branch
Galveston, Texas
John J. Moulds and his adventures in blood 
banking from the 1960s to 2011
John James Moulds started his career in 
immunohematology and transfusion medicine in 1964 at St. 
John’s McNamara Hospital in Rapid City, South Dakota, as a 
Medical Technology (MT) student. The medical directors were 
Dr. Geib and Dr. Frost, and his MT instructor was Mrs. Bonnie 
Fingerhut. It became obvious that blood banking was John’s 
favorite department. Here he is as a student doing blood typing 
(notice no gloves) (Fig. 1). There were three others in John’s 
class—Jo Ashburn, Mary Ramos, and Irene Coates (Fig. 2). 
One day, John and Jo were scheduled in the blood bank, and 
the supervisor of that department failed to show up for work. 
John and Jo just carried on, typing donor and patient blood, 
performing antibody screenings, and crossmatching and 
issuing blood. Bonnie Fingerhut was rather upset when she 
found out they were doing all this without supervision!
John worked at St. John’s for a while after graduation, 
and in December 1965 he took a job in a small laboratory 
at Chadron Community Hospital in Chadron, Nebraska, 
where he had attended college. He was the only technologist 
for several months until I was hired to help out. A variety of 
tests were performed, especially in the busy departments of 
hematology, chemistry, and blood banking. Unfortunately, 
there were no panels to identify antibodies, and they had to be 
sent out. John was almost always right on his guesses as to the 
specificities. One time he helped one of the physicians diagnose 
a patient with lupus erythematosus from the butterfly rash on 
the patient’s face.
John applied and was accepted to Specialist in Blood 
Bank (SBB) school in 1968 at War Memorial Blood Bank (now 
known as Memorial Blood Center) in Minneapolis, Minnesota. 
Here he is with the laboratory director, Eleanor Amberg, and 
his SBB instructor, Helen Arndt (Fig. 3). The medical director 
of the blood center was Dr. Herbert Polesky. John’s favorite 
department was the reference laboratory, which was directed 
by Jane Swanson, one of the pioneers in the field of blood 
groups. She would be the one who fueled his passion for the 
many fascinating aspects of the rare blood groups, many of 
which were identified or investigated in that laboratory. This is 
a picture of Jane and John from 1997 when she visited him at 
Gamma Biologicals in Houston (Fig. 4).
After graduation from SBB school, John was a research 
technologist at the blood center from 1969 to 1970 until he took 
over Jane’s position as supervisor of the reference laboratory.
The American Association of Blood Banks (AABB) rare 
donor file was moved from Chicago to Minneapolis in 1974, 
and John directed the activities until 1975. One of the first 
units of blood distributed internationally from Minneapolis 
was a group O, D–, Vel– rare unit of blood for a patient in 
South Africa. John was also a member of the AABB Reference 
and Rare Donor committee from 1972 to 1978; he chaired it 
from 1975 to 1978.
Early on John became involved in education when he 
and I were part of a team that presented American Society of 
Clinical Pathology (ASCP) paternity workshops. Drs. Herbert 
Polesky and Richard Walker gave the lectures, and John and 
I directed the “wet” workshops. Yes, “wet” and in hotels!! We 
also, of course, were the ones who prepared the samples. The 
workshops were held in Boston, Massachusetts, in 1971 and 
Atlanta, Georgia, and San Francisco, California, in 1972.
John founded the Serum, Cells, and Rare Fluids (SCARF) 
program in 1972. He contacted more than 60 reference 
laboratories, and approximately 30 responded. Each member 
agreed to send 10 mL of a rare or unusual sample once a year 
to each of the other members. John sent the first sample, which 
was blood from an Rh-null patient. It did not take long before 
the other 30 or so laboratories that had not responded wanted 
to join. The Rh-null sample was from Dr. Alvin Lebeck, a 
veterinarian in Wisconsin who John had become friends with 
when we went to Wisconsin on vacation to draw blood from 
him and his family (Fig. 5). This led to John being invited 
to give a talk in 1973 at the annual seminar of the AABB, 
which that year was called “A Seminar on Recent Advances 
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In this picture (Fig. 6) (left to right standing) are John Case 
(Director of Regulatory Affairs), Dr. Jacob Struck (Research 
and Development), Leah Walthers, Barbara Fryer, Mary Ann 
Bridges, John Moulds, and (seated) myself and Pamela Lacey. 
We were very fortunate to have the two gentlemen to turn to 
for advice on rare cases and production of special solutions. We 
should also recognize two administrative assistants, Barbara 
(Babs) Smith and Rose Quiroz.
The consultation laboratory was certified by the state of 
Texas and eventually became a laboratory certified by the 
Clinical Laboratory Improvement Act (CLIA) and also an 
AABB Immunohematology Reference Laboratory (IRL). 
Around this time SCARF expanded into two groups, which 
now included international members sharing samples from all 
over the world. John also added a third group of small reference 
laboratories in the United States to assist them in building up 
their collection of rare cells, serums, and fluids. SCARF helped 
us to solve many blood group problems and build up one of 
the largest liquid nitrogen and plasma collections of rare and 
unusual samples in the world. It consisted of ABO subgroups, 
Rh typing discrepancies, polyagglutinable cells, high- and 
low-incidence antigens and antibodies, and, most importantly, 
family studies that would be very useful for molecular studies 
in the future. It also helped approximately 150 laboratories 
throughout the world solve unusual and difficult problems. As 
many know, John rarely tossed an interesting sample, and to 
this day, LifeShare Blood Centers in Shreveport, Louisiana, 
under the leadership of the CEO Margaret Wallace, MT(ASCP)
SBB, continues to preserve these rare samples, even though it 
can be very costly to maintain the rare cells in liquid nitrogen.
An official Gamma Tutorial was started for Gamma 
Biologicals customers in the United States that eventually 
in Immunohematology.” This was his first major presentation. 
The title of the talk was “Rhnulls: amorphs and regulators.”
While at the blood center, John was fortunate to work 
on samples from many patients with rare blood types and 
antibodies. He learned a great deal from his mentor and 
special colleague Jane Swanson, who always said that John 
was her “second son.” Some of these exciting cases included 
Rh-nulls, D, Dombrock, Colton, Cartwright, Gregory, Hy, 
Knops, York, JMH, Chido, and Rodgers, to name a few. Several 
early publications were (1) some observations on the T, Tn, 
and Sda antigens and antibodies that define them in 1972; (2) 
blood group U antigen on Rh-null leukocytes in 1974; and (3) 
observations on the Gya and Hy antigens and the antibodies 
that define them in 1975.
John was given the opportunity to become the Director 
of Consultation and Education at Gamma Biologicals, Inc., in 
Houston, Texas. The family moved in August 1975 from cold 
Minnesota to hot and humid Texas. I was offered the position 
of Supervisor of Consultation and Education. On the first 
day of work there were more than 75 samples waiting to be 
tested. At that time, and until 2004 when the laboratory was 
closed, Gamma Biologicals offered a service to their customers 
worldwide: a no-charge workup on difficult, unusual, and 
rare samples. Local SBB students had been invited to spend 
a week at Gamma Biologicals to learn the various aspects 
of reagent and red blood cell (RBC) screening and panel 
production. Three students from St. Luke’s Hospital (Carl 
Northam, Pamela Lacey, and Barbara Fryer) caught our eye, 
and shortly after the three graduated from MT school they 
were offered positions at Gamma Biologicals. Carl became the 
Supervisor of Quality Control, and Pam and Barb were hired 
in the Consultation and Education Department. They were the 
first of several technologists to work with us on samples and 
publish results of our findings on many interesting cases.
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Figure 1. John Moulds as a Medical 
Technology student at St. John’s McNamara 
Hospital in Rapid City, South Dakota, 1964.
Figure 3. John Moulds with the laboratory 
director, Eleanor Amberg, and his instructor, 
Helen Arndt, at the Specialist in Blood Bank 
(SBB) school at War Memorial Blood Bank 
(now known as Memorial Blood Center) in 
Minneapolis, Minnesota, circa 1968.
Figure 2. John Moulds with his classmates 
in medical technology—Jo Ashburn, Mary 
Ramos, and Irene Coates, circa 1964.
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Figure 4. John Moulds and Jane Swanson at 
Gamma Biologicals in Houston, Texas, 1997. 
Figure 5. Dr. Alvin Lebeck, a veterinarian in 
Wisconsin who was of the Rhnull phenotype, 
circa 1972.
Figure 6. Staff at Gamma Biologicals, 
Houston, Texas. Left to right standing are 
John Case (Director of Regulatory Affairs), Dr. 
Jacob Struck (Research and Development), 
Leah Walthers, Barbara Fryer, Mary Ann 
Bridges, John Moulds; seated are Marilyn 
Grandstaff (Moulds) and Pamela Lacey.would lead to International Tutorial programs. It began 
with two invited customers spending Monday through 
Friday working with the consultation staff on interesting 
samples and learning about blood groups. In 1980, a special 
laboratory was built that would accommodate 12 participants 
(sometimes more would be added by John as he hated to turn 
anyone away).
The first group of classes began in 1982, and six to eight 
classes were held during the year. Lectures were given by the 
consultation staff and other departments in the morning, and 
a “wet” laboratory was conducted in the afternoon, in which 
participants worked on almost every type of unusual sample 
using various techniques. More than 1000 blood bankers 
went through the Tutorial Program until it closed in 2006. 
Many of these participants are leaders today in the field of 
immunohematology, including several physicians.
As John read publications on various techniques, he would 
start making reagents that were needed to perform them. He 
then gave them to the consultation staff to use on cases, and 
would then publish the results. He even had his mother, Edith 
Moulds, growing Vicia graminea seeds to make our own 
lectin, and these details were outlined in a poster presented 
at the AABB. Most of the homemade reagents eventually 
became commercially available from Gamma Biologicals, and 
ultimately other reagent and RBC manufacturing companies 
followed suit on some of these. This subject will be discussed 
by Tony Casina in this issue.
As if this was not enough to keep John busy, he also traveled 
nationally and internationally giving talks on blood group 
findings, techniques, etc. John presented his second major talk 
in 1978 for the AABB Preconvention Seminar in Seminar on 
Perinatal Blood Banking. The topic was “Immunosuppression 
by Passive Antibody, Rh D Suppression—Rationale and Use 
and Antenatal and Postnatal Prophylactic Treatment.” Rh was 
probably one of his most favorite blood groups, and he was 
involved from the very beginning of his career with many of 
the new findings in this blood group system.
There were several other blood group systems John had 
a special interest in, one of which was Colton, in which the 
first Co(a–b+) was discovered in Minneapolis and a patient 
sample studied in Houston by John and the staff was the first 
Co(a–b–). He was very proud to be included in publications 
with Peter Agre, who received the Nobel Prize for Chemistry 
for his work on aquaporin 1 and Colton and also was the 
recipient of the Karl Landsteiner award from the AABB.
Cromer was another blood group system that John 
became involved with, when one of the staff worked on a 
sample from the second example of IFC negative, which is the 
null of Cromer. In collaboration with Cyril Levene in Israel our 
laboratory described Dr in the Cromer system, and later on 
John would work with Bogdan Nowicki in Houston to describe 
a hemagglutinin of uropathogenic Escherichia coli recognizing 
the Dr blood group antigen.
John was also very fortunate to be able to work with 
the German scientist Wolfgang Dahr, who had a particular 
interest in the MNS and Gerbich blood group systems. It was 
interesting to see the two of them in the laboratory preparing 
membranes and testing unusual human and monoclonal 
antibodies.
John was a member of several professional organizations 
(often chairing committees) and editorial boards. The 
organizations included AABB, ASCP, South Central 
Association of Blood Banks (SCABB), International Society 
of Blood Transfusion (ISBT), and Invitational Conference of 
Investigative Immunohematologists (ICII).
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He was on the ISBT Working Party on Terminology 
for Red Cell Surface Antigens since 1980 and chaired the 
committee from 1990 to 1994. He also was on the 3rd and 
4th International Workshop and Symposium on Monoclonal 
Antibodies Against Red Blood Cells and Related Proteins 
program committees in 1995 to 1996 and 2000 to 2001. 
Both of these committees helped shape the organization and 
naming of antigens in the human blood groups and set criteria 
for inclusion in a blood group system.
John received numerous honors and awards from 
various organizations for his contributions to the field of 
immunohematology, transfusion medicine, and education. 
The first of these was the L. Jean Stubbins Award from 
SCABB in 1979, which he and I shared (Fig. 7). Next were 
the Ivor Dunsford Memorial Award from AABB in 1983, 
Angelyn Konugres Lectureship from MABB in 2001, Sally 
Frank Award Lectureship from NBF/AABB in 2003, Kay 
Beattie Award Lectureship, Michigan Association of Blood 
Banks in 2005, L. Jean Stubbins Memorial Lectureship from 
University of Texas Medical Branch in Galveston, Texas, in 
2007, SCABB 49th Annual Meeting Scientific Award Lecturer 
from SCABB/CBBS in 2007, Award for Technical Excellence 
from America’s Blood Centers/Institute for Transfusion 
Medicine in 2011, and the Larry L. Trow Memorial Education 
Award from SCABB in 2011.
One honor that John received outside the field was 
recognition by Chadron State College in Chadron, Nebraska, 
when he was presented with the Distinguished Alumni Award 
in 2009 for his many accomplishments. Before the awards 
ceremony he gave a talk to the various classes of premedical 
students on how to succeed in whatever you set your sights on 
and reach for the stars.
Figure 7. John Moulds receiving the L. Jean 
Stubbins Award from SCABB in 1979.
Figure 8. John Moulds with his mother, 
Edith Moulds, and his daughter, Terri 
Moulds Bowen, PhD, upon receiving the 
Distinguished Alumni Award from Chadron 
State College, 2009.
Figure 9. John Moulds with his mother, Edith 
Moulds, his daughter, Christine Moulds-
Merritt, MD, FACS, and his grandsons, Daniel 
Bartley Merritt III (age 13) and Matthew 
Ryan Merritt (age 9), at the dedication of the 
LifeShare laboratories in 2011.
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While at Gamma Biologicals, John went on to become 
Chief Operations Officer and Executive Vice President, then 
President and Chief Science Officer. He helped automate 
various aspects of manufacturing and brought computers into 
the workplace. He was also a member of the board of directors 
from 1992 to 1997.
John left Gamma Biologicals in 1997 and worked for 
a year as a research associate in the Department of Medical 
Hematology, Baylor College of Medicine, in Houston, Texas, 
and from there he joined Ortho Clinical Diagnostics in Raritan, 
New Jersey, in various capacities in research.
John left Ortho in 2004 to become Director of Scientific 
Support Services at LifeShare Blood Centers in Shreveport, 
Louisiana. One of the first items on the agenda was to attend 
a workshop and read articles on monocyte monolayer assay 
(MMA) and develop the assay at LifeShare for assisting in 
determining the clinical significance of antibodies when 
patients needed to receive incompatible blood. Again, he led 
this laboratory and the staff to become a source of knowledge 
and expertise for the reference laboratory at LifeShare and 
other laboratories throughout the blood bank community. 
This Scientific Support Laboratory has also become one of the 
leaders in the field of DNA technology, led by Dr. Joann Moulds. 
In February 2011, LifeShare honored John with a dedication 
ceremony at which the reference and scientific laboratories 
were renamed the John J. Moulds Reference and Scientific 
Support Laboratories for John’s lifetime accomplishments. 
Many colleagues attended this dedication, and others sent 
letters of their personal memories of John.
On a personal note, John has two daughters who went on 
to college and got advanced degrees (there was no question 
in John’s mind that they would). He was very proud of them 
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and their accomplishments. One, Terri Moulds Bowen, PhD 
(Fig. 8), received her advanced degree in biology from UCLA 
in California and loved working in the laboratory and research 
(like her father). However, she has now found a new career in 
teaching, again like her father, who never turned down anyone 
who would ask him for advice or to give a talk, anywhere in 
the world. His other daughter, Christine Moulds-Merritt, MD, 
FACS (Fig.9), who completed a surgery residency at Scott and 
White in Temple, Texas, is a general surgeon and specializes in 
breast surgery.
John’s two grandsons, Daniel Bartley Merritt III (age 13) 
and Matthew Ryan Merritt (age 9) (Fig. 9), have also inherited 
some of John’s traits—his skill for seeing a problem and 
coming up with solutions and his sense of humor. They both 
seem to find science their favorite subject in school, so it will be 
interesting to see what lies ahead for them in the future. They 
also have gone deer hunting with their mother and father, just 
as John did with his dad, and the oldest grandson got his first 
buck last year. The younger one also shares John’s love for 
fishing.
And lastly, John’s love of animals, especially dogs (Fig. 
10), has led to his rescuing them from numerous situations 
and giving them a home filled with kindness and love.
What will be John’s legacy, you might ask? Some say 
it is the international SCARF program he founded, which 
is still active today. I say this and his love of blood groups, 
high- and low-incidence antigens, investigating unusual test 
results, preparing test solutions, his sharing of the knowledge 
he gathered over the years, his joy in teaching, and his sense 
of pride in what he did throughout his career. He always 
reminded us to “never forget the history.” He loved the stories 
that went with the discoveries of the blood groups and the 
various antigens and antibodies.
Marilyn K. Grandstaff Moulds, BA, MT(ASCP)SBB 
Immunohematology Specialist
John Moulds Reference Laboratory 
Shreveport, Louisiana
The antibodies that no one wanted to work on—
except John
When preparing the titles for our talks at the laboratory 
dedication, one of the laypersons who organized the meeting 
read my title and commented, “Oh, you mean like little Orphan 
Annie Bodies.” And indeed, the HTLA group could have just as 
easily acquired this name had it not been for John’s persistence 
to investigate them. Those of you who have heard me speak 
know of my campaign to stomp out the term HTLA. However, 
to understand where we are today means that we have to 
appreciate the history behind the terminology—a history in 
which John Moulds was a key player.
The beginning of the term HTLA goes back to the early 
1970s when the American Association of Blood Banks 
(AABB) and American Red Cross reference laboratories 
had joint meetings actually consisting of wet workshops! 
The participants would bring antibodies to high-incidence 
antigens and antibodies to low-incidence antigens and try 
to pair them up or place them in a blood group system. But 
there always seemed to be a group of antibodies that never 
fit into a known blood group system. These antibodies were 
notoriously weak and difficult to work with, hence the name 
serum hemagglutinins of inscrutable type proposed by John 
Judd. The resulting acronym made some serologists snicker, 
whereas others were offended. So finally Jane Swanson, 
Delores Mallory, and John Moulds came up with a descriptive 
name of high titer–low avidity, or HTLA, antibodies. 
Technologists would come to automatically use this as an 
explanation for weak anti-human globulin (AHG)–reactive 
antibodies, and others would incorrectly use the name HTLA 
antigens. John was to live long enough to regret that name. 
In fact, he once wrote that “serologists frequently use slang 
or colloquial statements that are intended to be descriptive of 
the general problem.… These slang terms are not intended to 
define an antibody specificity, but rather to roughly describe 
the serological results.”
So what are the serologic characteristics of the HTLA 
antibodies? Probably their hallmark is their weak and variable 
reactivity at the AHG phase of testing. The reactions can range 
from microscopic + to 1+ or sometimes 2+. Although they were 
initially believed to be of high titer (>64), not all exhibit this 
characteristic and often the titer is dependent on the indicator 
cell chosen for testing. In general, they are not enhanced with 
low-ionic strength saline or polyethylene glycol, and the effect 
of enzymes varies with the individual specificities. Cord cells, Figure 10. John Moulds with Bodie.
124 IMMUNOHEMATOLOGY, Volume 27, Number 4, 2011
S. Nance et al.
as well as older stored red blood cells (RBCs), often give weaker 
or negative reactions. Finally, the antibodies have not been 
reported to bind complement or cause hemolytic transfusion 
reactions. The antibodies originally meeting these criteria 
included anti-JMH, -Yta, -Gya, -Hy, -Joa, -Ch, -Rg, -Kna, -Knb, 
-McCa, -McCb (McCc/McCd/McCe), -Sla, -Vil, -Yka, and -Csa. 
Each of these has now been placed in a system recognized by 
the International Society of Blood Transfusion, and they are 
described in subsequent sections. The exception is Csa, which 
remains in a collection of two antigens.
System 011-YT
YT (Cartwright) existed as a blood group system before 
the terminology HTLA gained favor; however, because of the 
antibodies’ weak reactivity, many placed them into the HTLA 
group. Presently there are two known antigens, Yta and Ytb, and 
only one reported example of a true null phenotype Yt(a–b–). 
John’s involvement with this system was at the population 
genetics level. Working with Dr. Cyril Levine in Israel he 
studied Israeli Jews and they showed that this ethnic group had 
a high incidence of Yt(b+), approximately 25 percent. The Ytb 
antigen has also been found with increased  incidence among 
Arabs but is almost nonexistent in Asians. Therefore, one of 
the best sources for Yt(a–) donors is the Jewish population.
In the early 1990s, Dr. Dave Anstee in Bristol, United 
Kingdom, and Dr. Marilyn Telen in Durham, North Carolina, 
both reported that the YT system antigens were carried on 
a protein known as acetylcholinesterase. Thus, paroxysmal 
nocturnal hemoglobinuria type III RBC, which lack all 
glycophosphatidylinositol-linked proteins, will have the 
acquired phenotype Yt(a–b–). A mutation at codon 322 
changes histidine (Yta) to arginine (Ytb). Using this known 
single nucleotide polymorphism, DNA-based methods have 
now been developed to accurately type for YT.
System 014-DO
John was destined to be involved with the Dombrock 
system because his mentor at Minneapolis War Memorial 
Blood Bank, Ms. Jane Swanson, was the first to report anti-
Doa. He was able to squirrel away probably the biggest stash of 
anti-Doa on the continent, and he used it sparingly but wisely. 
Being the generous soul that he was, John shared some of this 
antibody with Dr. Nakajima from Japan, and they were able to 
show that Doa was a low-incidence antigen in that population. 
Later, with Dr. Yoshida Okubo, he would report the first 
example of Gy(a–) with anti-Gya in the Japanese.
Anti-Hy (Holley) was reported in an abstract in 1967, 
and several more examples were published, all being found 
in Blacks. The consultation laboratory that John directed 
at Gamma Biologicals studied a number of these unique 
antibodies and described a subdivision that they named Jca. 
Although others thought that Jca was synonymous with Joa, 
John always believed that they were different, and there is 
some emerging molecular data that may support his theory. 
John would also be the first to recognize an association 
between Hy and Gya as all Hy– Blacks were Gya weak. Finally 
an explanation came forth in 1995 when Banks reported that 
RBCs having the rare phenotype of Gy(a–), Hy–, Jo(a–) were 
also Do(a–b–), i.e., Gy(a–) was the null for this blood group 
system. This is a rare null phenotype occurring in less than 
1:10,000.
The Dombrock antigens would later be determined to be 
located on the adenosine 5′-diphosphate ribosyltransferase 
4 protein, and the molecular mechanism for each would be 
identified (Table 1). John was quick to remind technologists 
that although most HTLA antibodies are considered clinically 
insignificant, anti-Doa had caused delayed hemolytic 
transfusion reactions. He believed that the availability 
of donors molecularly typed for Doa and Dob would be a 
significant improvement in supplying safer blood for these 
antibody producers.
System 017-Ch/Rg
John hated using “selected cells” to determine antibody 
specificities. He thought that serologists should use their 
knowledge of the antigen biochemistry and be able to 
manipulate the test medium. The remaining systems 
exemplify this opinion. After the identification of Chido 
(Ch) and Rodgers (Rg) antigens on the fourth component of 
complement, specifically C4d, John theorized that one could 
enhance the antibody reactivity by increasing the amount of 
C4 on the reagent RBC. In fact, that’s just what he did. In a 
report in Transfusion, John Judd and John Moulds showed 
that you could use a simple sucrose method to put more C4 
Table 1. Molecular background for the common DO antigens
Phenotype Nucleotide Exon Amino Acid
Do(a+) A 2 Asn265
Do(b+) G 2 Asp265
Hy+ G 2 Gly108
Hy– T 2 Val108
Jo(a+) C 2 Thr117
Jo(a–) T 2 Ile117
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on the RBC, and with the increased number of antigen sites, 
anti-Ch or anti-Rg could react as a direct agglutinin. This, 
in combination with the fact that ficin destroyed antibody 
reactivity, made it simple to identify anti-Ch or anti-Rg. The 
fact that some Ch/Rg antibodies have caused anaphylactic 
reactions when transfusing plasma components makes it 
important to be able to at least get the HTLA antibody into the 
correct system.
Working with Dr. Carolyn Giles, John and the staff at 
Gamma Biologicals helped define six Chido antigens and three 
Rg antigens. Later, Dr. Yung Yu would work with Carolyn to 
define all of these at the molecular level. The rare null for this 
system would be the total C4-deficient patient, of which there 
were fewer than 20 known in the world. This fact would lead 
to John’s next mark on the Ch/Rg system, i.e., mentoring a 
struggling graduate student (Fig. 1).
Dr. Joann Moulds would go on to investigate two C4-
deficient (Ch–/Rg–) brothers as well as the association of the 
Rg– phenotype with systemic lupus erythematosus. Using 
monoclonal anti-Ch and anti-Rg, assays were developed 
to quantify these plasma proteins. One of the surprising 
observations from this work was that Blacks had higher levels 
of C4B in their plasma, i.e., Chido substance, which was the 
result of a C4B gene duplication. This finding validated John’s 
earlier observations that Black donors made better C4-coated 
RBCs for the manufacturing of Gamma Biological’s reagent 
quality control kit.
System 022-KN
Once again, John’s Minneapolis connection would 
contribute greatly to his involvement in a blood group system, 
this time Knops. Mrs. Knops was identified as having anti-
Kna, and one serologically compatible donor was found, i.e., 
Margaret Helgeson. Margaret was a technologist at the blood 
bank and found later that she was not only Kn(a–) but was, in 
fact, the serologic null for the system. She became infamous 
when John made her a regular contributor on the international 
exchange he founded known as SCARF (Serum, Cells, and 
Rare Fluid Exchange).
When John and Marilyn Moulds went to Gamma 
Biologicals, they continued to work on the weak antibodies 
no one cared about and began adding new specificities to the 
KN system. These included the Hall serum (anti-Knb), anti-
McCa, anti-Sla (Swain-Langley or Sl1), and anti-Vil (Villien or 
Sl2). The latter two were only presented in an AABB abstract 
because of a difference of opinion with another collaborator, 
Dr. Lyndall Molthan. Over John’s objections, Dr. Molthan 
continued to add these new specificities to the McCoy locus, 
i.e., McCc, McCd, McCe, etc. Molecular analysis would later 
prove the Gamma Biologicals group correct that these were 
separate mutations on the Knops protein.
As if there were not enough Mouldses involved with the 
HTLA story, the new Dr. Moulds would take on Knops as 
one of her postdoctoral projects. Armed with many of the 
original antisera provided by John, she found that the Knops 
antigens resided on complement receptor type one (CR1). The 
variability in reactivity as well as the Helgeson phenotype could 
now be explained by the known inherited RBC expression 
polymorphism of the CR1 gene.
But this was just the tip of the iceberg, and John’s collection 
of antigen-negative cells and Knops antisera would prove 
invaluable for the next set of investigations. Dr. Lou Miller 
(of Duffy blood group and malaria fame) was now studying 
Plasmodium falciparum malaria and the phenomenon known 
as rosetting. Because John had shown that certain Knops 
phenotypes such as Sl(a–) and McC(a–) occurred more 
frequently in Blacks, Joann postulated that this may also be a 
protective phenotype. So off to Africa (Mali) the two traveled 
Figure 1. John the consummate mentor (for Dr. Joann Moulds and 
many others).
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to begin what would become a 6-year project. The data are 
too numerous to discuss here, but the conclusions were as 
follows: (1) the African haplotype McC(a–b+), Sl(a–), KCAM-
negative results in reduced rosetting of infected RBCs and 
less severe malaria; (2) in Asia the protective phenotype is the 
Helgeson type, which also results in reduced rosetting; and 
(3) the most virulent forms of P. falciparum use CR1 (Knops) 
as an alternative invasion pathway into the RBCs. So much 
good scientific information has come from those silly serologic 
studies that John championed.
System 026-JMH
Perhaps it is fitting that the last system arising out of the 
HTLA group would share part of John Moulds’ name, i.e., JMH 
(John Milton Hagen). This strange collection of antibodies went 
by many names: The Boys, The Cats, The Over 60s, etc. This 
was because many of the first examples were found in elderly 
men or women who owned cats. The antibodies were rather 
unexciting, not causing hemolytic disease of the newborn or 
fetus or hemolytic transfusion reactions, and occasionally one 
would appear to be an autoantibody. But again, John would be 
involved in elevating this group to full system status. In 1991, 
he and Marilyn Telen published a paper in Blood locating JMH 
on a phosphatidylinositol-linked membrane protein. Later 
this was identified as semaphorin A (SEMA7A or CD108). 
Using samples sent to him by Dr. Cyril Levine many years 
earlier, John collaborated with Dr. Axel Seltsam to expose the 
molecular diversity of the JMH gene. Presently there are six 
antigens identified from what was once believed to be a single, 
annoying antibody specificity. It remains to be seen what role 
these antigens may play in the modulation of natural killer cell 
function.
Summary
John’s dogged determination to work with and identify 
the HTLA group of antibodies has certainly led to many 
important discoveries. From a medical technology student to 
a world-renowned immunohematologist, John Moulds has 
come a long way (Fig. 2). And we, his students, friends, and 
collaborators, “stand up and cheer for this doer, this achiever, 
the one who recognized the challenge and did something 
about it” (paraphrased quote from Vince Lombardi). We are 
glad you did, and we will never forget your many scientific 
contributions.
Joann M. Moulds PhD, MT(ASCP)SBB
Director, Scientific Support Services
LifeShare Blood Centers
Shreveport, Louisiana
If a reagent can be made, John J. Moulds can  
make it
John J. Moulds has had a dramatic impact on blood 
bank technologists worldwide, making their lives easier when 
performing pretransfusion testing and problem solving. 
John’s many contributions to the development of commercial 
reagents allow technologists to perform testing without 
the need for extensive preparation of reagents and without 
intensive method and technique applications. “Professionally 
developed and manufactured reagents for professional use 
that simplify the life of the blood banker …” 
On February 19, 2011, the John J. Moulds Reference 
and Scientific Support Laboratories were dedicated to John J. 
Moulds. This is a reiteration of the presentation, “If a reagent 
can be made, John J. Moulds can make it,” delivered at this 
ceremony.
When I was asked in the fall of 2010 to participate as a 
speaker at the symposium and laboratory dedication of the 
John J. Moulds Reference and Scientific Support Laboratories 
at LifeShare Blood Centers, I was both humbled and proud 
of that opportunity to honor both a great friend and mentor 
for the many accomplishments he achieved throughout his 
illustrious career. However, before I go into the focus of my 
Figure 2. John as a medical technology graduate (left) and as 
Director of Scientific Support Services at LifeShare Blood Centers 
(right).
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presentation at that dedication, I want to share a personal 
story, which I shared at the dedication as well, about John’s 
influence on my career in the transfusion medicine industry.
My first encounter with John was via the phone. I was 
a full-time employee at the Medical College of Pennsylvania 
in Philadelphia, Pennsylvania, where I had just graduated 
from the medical technology internship program. My blood 
bank manager asked me to call Gamma Biologicals and ask 
for John Moulds to find out “what was wrong with these 
screening cells.” One of the antibody screening cells was 
showing reactivity with serum samples from a few patients; 
subsequent antibody panel identification testing showed 
results with reactivity that appeared to have no antibody 
specificity. John kindly took the time to explain to me that the 
particular antibody screening cell expressed the Bga antigen 
and was likely involved because other cells that were tested 
on the antibody identification panel had “Bg” expression. 
As typical of the teacher in John, he patiently answered 
my questions and clarified what he could in light of the 
conversation being a phone discussion.
I walked away from that call impressed. About 2 years 
later, the sales representative from Gamma Biologicals 
happened by the hospital the week before the next meeting of 
the local antibody club, the Delaware Valley Blood Bank Club, 
which I had planned to attend and which featured John as the 
speaker. The representative made me an offer that I jumped 
at: after John was done speaking at the meeting, would I like 
to have a drink with him at a local “watering hole”? So after 
talking a little bit about the blood bank consultation service 
at Gamma and his travels talking about blood group serology 
and blood banking reagents, John asked if we could talk about 
something other than blood banking (I am sure that, as is the 
customary topic of conversation between sales representatives 
and customers, all John had done that day was talk about blood 
banking). So we talked about where we grew up, hobbies like 
hunting and fishing, and an old Corvette that he was trying to 
rebuild. Again, I walked away significantly impressed by the 
man and his career.
Because of these encounters with John, my experiences 
with teaching students, working on just about every antibody 
that was received in the hospital laboratory, and attending 
local and state blood bank meetings, I was hooked on blood 
banking. So my fate was sealed. His influence fueled my desire 
to work for a blood group reagent manufacturing company, 
focusing on blood group serology and the use of blood bank 
reagents. In 1983, I started my career in the commercial 
industry working for Biological Corporation of America (BCA) 
in the Blood Bank Consultation Service.
Over the years, John and I encountered each other at 
blood bank meetings. Always open to speaking at local, state, 
regional, national, and international meetings, John shared 
his knowledge with the blood bank masses.
In the early 2000s, I would get to work directly with John 
at Ortho Clinical Diagnostics. During more than 30 years of 
interactions with John, his willingness to share his knowledge, 
to discuss cases, and to be a mentor has had a great impact 
on my career. I am sure there are many out there who have a 
similar story to share about John.
Many of John’s contributions to the development of 
commercial reagents have either simplified or solved challenges 
for the transfusion service or reference laboratory medical 
technologist in applying testing methods and techniques. With 
John’s guidance and insights, and the assistance of colleagues 
at Gamma Biologicals, significant contributions were made to 
the introduction of these reagents.1
Now on to the contributions that John has made to the 
blood banking world from a commercial blood bank reagent 
perspective that could be applied in testing by just about any 
medical technologist willing to follow instructions. So yes, “If 
a reagent could be made, John J. Moulds can make it.” Figure 
1 provides a timeline summary of the release of these various 
commercial blood bank reagents.
1970s
One of John’s first uniquely developed commercial reagents 
in the early 1970s was stable complement-coated cells. Having 
to prepare special reagents, select the right donor red blood cell 
(RBC) to coat, and attempt to stabilize the complement coating 
on the RBC when preparing complement-coated RBCs are 
true challenges. The introduction of a commercially available 
ready-to-use stabilized complement-coated cell to quality 
Figure 1. Adapted timeline for introduction of reagents.2
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control anticomplement antiglobulin reagents certainly made 
it easy to assure that anti-human globulin reagents containing 
anticomplement activity were performing acceptably. No 
longer was it necessary to spend hours preparing materials, 
qualifying the “right” donor, coating the cells, and in the 
end having to quality control the prepared complement- 
coated cells.
Proteolytic enzymes and their effects on RBC structure 
and antigens have been extensively studied. Use of enzymes in 
blood group serology was limited to those experienced in their 
preparation and use. Variations in enzymes and treatment 
approaches created variability in observed test results. In 
the late 1970s, John, along with the consultation service and 
RBC production departments at Gamma, had prepared ficin-
treated panels, and John shared them with other serologists 
in a few reference laboratories throughout the United States. 
After doing this several times during the year, John found 
the number of reference laboratories wanting to get in on 
the “enzyme panel” expanding. The first commercially 
available enzyme-treated panel was born. The Gamma ficin 
panel became popular because it eliminated the need for the 
special preparation required for enzymes, and for treatment 
standardization and it had stability, so that the product had 
a longer shelf life compared with the self-made preparations. 
Now not only reference laboratories but transfusion service 
laboratories could perform enzyme antibody identification 
panels using the commercial panel. Resolving some complex 
antibody problems with enzymes now became simpler and 
quicker, decreasing turnaround time.
The ability to remove the coating antibody from RBCs to 
identify it is a very useful tool for solving antibody problems 
associated with autoimmune hemolytic anemia, hemolytic 
disease of the newborn and fetus, drug-induced hemolysis, 
and hemolytic transfusion reactions. Elution procedures for 
preparing eluates were often limited to a safe but ineffective 
method such as a 56°C heat elution or choosing a chemically 
oriented method with potential dangers in its use. The discovery 
that an acidic solution could be used to elute antibody from 
RBC stroma created a safe, effective way to produce an eluate.3 
John took this information and created the first commercially 
available elution kit, Gamma Elu-Kit I, which used a series of 
reagents including a solution of digitonin, a wash solution, an 
acid solution, and a buffer solution to create a popular approach 
to performing elution.
Later in the 1970s the introduction of the first licensed 
anti-Cob, with John’s leadership, led to a stream of new reagent 
antisera to “rare antigens” and to a variety of blood group 
antigens during the next decade.
John followed with two reagents formulated to help 
enhance antibody detection and identification tests. The low-
ionic-strength saline (LISS) solutions method, as described 
by Löw and Messeter,4 used RBCs that required the cells 
to be washed and suspended in the solution for use. John 
helped develop two reagents, Gamma LO-ION and Gamma 
N-Hance. The Gamma LO-ION product, an additive-based 
LISS reagent, used the traditional LISS solution along with a 
high-molecular-weight protein (polyvinylprolidine) to create 
a popularly used tube-based LISS additive. Gamma N-Hance 
used the traditional LISS-based approach combined with 
bovine serum albumin as part of the formulation. Both additive 
methods allowed for any properly prepared RBC suspension to 
be tested easily without special preparation of the cells in a 
LISS solution.
1980s
The 1980s brought a plethora of new innovative 
commercial reagents driven by John. Polyagglutinable 
cells are generally easy to define and identify with the use 
of the right lectins that react and agglutinate certain RBC 
antigens. John enjoyed working with cells that demonstrated 
polyagglutination. Making life easier for technologists working 
with polyagglutinable cells, John worked to produce and 
standardize lectin reagents for manufacturing.  An abstract 
“Care and cultivation of Vicia graminea” by John and others in 
the early 1980s kept it all in the family, as even John’s mother, 
Edith, made a significant discovery.5 (Fig. 2.) V. graminea, 
the plant from which the seeds for the lectin are harvested, 
is actually in a dormant state when it looks as if the plant has 
died. Edith found that the plant starts to grow again in the 
spring to produce seeds (personal communication, Marilyn 
Figure 2. Tony Casina and Edith Moulds at the dedication of the 
LifeShare laboratories to John Moulds in 2011.
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Moulds). An anti-N lectin (V. graminea) was developed and 
commercialized through these efforts. In the early 1980s, the 
Gamma Lectin Kit, with its four lectins, Arachis hypogaea, 
Salvia sclarea, Salvia horminum, and Glycine max (soja), 
allowed the identification of the most common forms of 
polyagglutination. The kit delivered the convenience of a 
manufactured standardized set of lectins without all of the 
“grinding and refining.”
The presence of antibody on RBCs can be quite impairing 
when attempting to antigen type RBCs. The removal of 
antibody from direct antiglobulin (DAT)-positive RBCs had 
traditionally been attempted by gentle heat elution to effect 
removal of antibody from the RBCs. This method was time 
consuming and often did not work very effectively. The 
discovery that chloroquine diphosphate could elute antibody 
effectively from most RBCs without significantly affecting 
antigen structure led to John’s development of a manufactured 
reagent, Gamma-Quin. This reagent could be used to remove 
antibody from DAT-positive RBCs, which allowed the use 
of antiglobulin-based typing reagents to test these RBCs for 
other blood group antigens.
In the mid-1980s, John drove innovative improvements 
to the Elu Kit I elution kit by introducing the capability of 
eluting antibody from intact RBCs. This innovation eliminated 
the need to wash the stroma free of hemolysis created by the 
digitonin lysis of RBCs and further reduced the turnaround 
time to obtain a quality eluate. Additionally, the remaining 
intact RBCs could be used for antigen typing in the appropriate 
circumstances.
The middle 1980s brought two manufactured reagents, 
which addressed the needs of obstetrical patients: Gamma 
Fetal Bleed kit and Gamma r-set antibody screening cell. 
John and the consultation staff formulated the Fetal Bleed 
Kit based on the Sebring-Polesky procedure6 for fetomaternal 
hemorrhage testing. This kit made the evaluation of 
fetomaternal hemorrhage an easy-to-perform blood bank 
test. The introduction of the Gamma r-set screening cells, 
of which John directed the design, simplified dealing with 
patients, particularly obstetrical patients who had received 
Rh immunoglobulin and had anti-D, eliminating the need to 
perform standard antibody identification in these patients. 
This simplified the process of finding selected cells for testing 
when anti-D is present.
With the innovation in the 1980s of monoclonal antibody 
technology in blood group serology, John introduced the first 
monoclonal antiserum for blood group antigen testing, anti-
He. He was instrumental in the introduction of additional 
specificities to the Gamma-clone line of monoclonal antibodies, 
including anti-Mg, -M, -N, -Lea, -Leb, -P1, and -K.
1990s
Unique new reagents continued appearing in the 
immunohematology testing market, flowing from a concept 
in John’s mind to a manufactured commercialized reagent. 
In the early 1990s John took a recently identified method 
for detecting and identifying blood group antibodies using 
polyethylene glycol (PEG), a test that Nance and Garratty7 
published in the late 1980s, and produced a product that can 
be used in tube-based tests for antibody detection that showed 
greater sensitivity with some blood group antibodies. The 
combination of PEG and LISS solution led to the Gamma PeG 
reagent that delivered the sensitivity of PEG in a convenient 
commercially prepared reagent.
Later in the 1990s John revolutionized the way 
antiglobulin reagents are produced, introducing the first 
monoclonal-based anti-IgG that eliminated the need to use 
rabbit-sourced anti-IgG. This murine monoclonal antibody 
had unique specificity in that it did not detect antibodies of 
the IgG4 subclass, which have been shown to rarely have 
any clinical significance. Additionally, this monoclonal anti-
IgG allowed for the development of the only total monoclonal 
polyspecific anti-human globulin (anti-IgG, -C3d).
2000s
John brought his innovative thinking and problem-solving 
skills to Ortho Clinical Diagnostics in 2000. Applying those 
skills, he helped resolve challenges with immunohematology 
products used worldwide and contributed to the development 
of new reagents.
It is obvious that John’s unique thinking and practicality 
afforded him the knowledge and wisdom to take complex 
technical processes and procedures and simplify them. 
That ability has led to the many unique immunohematology 
reagents that are used by medical technologists throughout 
the world to perform test procedures that normally would not 
be available to them.
I have only scratched the surface of the many reagents 
that John J. Moulds has had some hand in formulating into 
a medical technologist–friendly usable tool for immunohema-
tology testing and problem solving. Professionally developed 
and manufactured reagents for professional use that simplify 
the life of a blood banker …
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John will be missed by the many people he touched with 
his knowledge, wisdom, and mentorship. Personally, John was 
a great friend and I will miss him tremendously.
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It was with great humility, admiration, and pleasure 
that I attended the symposium and dedication of the John 
J. Moulds Reference and Scientific Support Laboratories 
at LifeShare Blood Centers in Shreveport, Louisiana, on 
February 19, 2011. John had been a member of the editorial 
board of Immunohematology since 1997. During that time, 
John had contributed to the journal through his innovative 
input to the journal process and format at the annual journal 
breakfast meetings at the AABB conference as well as through 
his timely and thorough review of manuscripts submitted for 
possible publication. John’s suggestion of providing serologic 
information in removable centerfold format in the journal will 
be implemented in this issue. His interest in the antibodies to 
low-incidence antigens led to his being asked to write a review 
of these important but sometimes forgotten blood group 
antigens. However, despite his intentions, time did not allow for 
this publication. I was honored to present John with a plaque 
commemorating his many years of insight, inspiration, and 
service on the board of Immunohematology at the LifeShare 
laboratory dedication (Fig. 1). John will be long remembered 
for his many contributions to the journal Immunohematology 
as well as to the field of transfusion medicine.
Cynthia Flickinger, MT(ASCP)SBB
Managing Editor, Immunohematology
American Red Cross Biomedical Services
Penn-Jersey Region
Philadelphia, Pennsylvania
Figure 1. Cindy Flickinger presenting 
commemorative plaque to John Moulds 
at LifeShare Dedication in 2011.
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